Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 3Recurrence 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Immunoglobulin Light-chain Amyloidosis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Glioblastoma 1Fibrosis 1Fallopian Tube Neoplasms 1Dysplastic Nevus Syndrome 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy 4Pemetrexed 4Carboplatin 4pembrolizumab 3osimertinib 3aflutinib 3Radiosurgery 3Drug Therapy 3toripalimab 2Docetaxel 2tislelizumab 1sugemalimab 1lenvatinib 1cemiplimab 1brigatinib 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Surgical Procedures, Operative 1S 1 (combination) 1Platinum Compounds 1Platinum 1Pharmaceutical Preparations 1Paclitaxel 1Neoadjuvant Therapy 1JDQ443 1Immune Checkpoint Inhibitors 1HM781-36B 1Gemcitabine 1Diphenhydramine 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × Pharmaceutical Preparations × 1 year × Clear all
NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
118 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡